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Abstract
E2F, the principal target of the tumor suppressor pRB, plays crucial roles in tumor sup-
pression. Upon dysfunction of pRB, E2F activates tumor suppressor genes such as ARF, 
an upstream activator of the tumor suppressor p53, resulting in the induction of apop-
tosis and tumor suppression. The E2F activity that activates the tumor suppressor genes 
is detected only in cancer cells and not in normal growing cells. The E2F activity can 
drive selective suicide gene expression and induce apoptosis specifically in cancer cells. 
Thus, the E2F activity provides a beneficial tool to specifically target cancer cells in cancer 
treatment.
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1. Introduction
A human body consists of 37 trillion cells and the cell number is maintained by a balance of 
cell death and cell proliferation. As aged cells are eliminated by cell death, new cells are sup-
plied by cell proliferation to retain appropriate cell numbers. To maintain homeostasis, cell 
proliferation is strictly regulated by growth signals. Cell proliferation is also induced by abnor-
mal growth stimulation such as overexpression or constitutive activation of oncogenes, which 
leads to tumorigenesis [1]. To protect cells from tumorigenesis, mammalian cells harbor tumor 
suppressor pathways, principally mediated by pRB and p53 [2, 3]. The RB pathway consists of 
pRB and upstream regulators such as cyclin-dependent kinases (CDKs) and CDK inhibitors. 
© 2018 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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The p53 pathway consists of p53 and upstream regulators such as HDM2 and ARF. The RB 
pathway and the p53 pathway suppress tumor formation by the induction of cell cycle arrest or 
apoptosis. The forced inactivation of both pathways in normal cells renders cells tumorigenic 
and both pathways are disabled in most cancers, indicating that these two pathways play piv-
otal roles in tumor suppression in normal cells.
The transcription factor E2F, the principal target of the RB pathway, plays central roles in cell 
proliferation by activating a repertoire of growth-related genes. Consistent with this, overex-
pression of E2F1, an activator type of E2F family members, in quiescent cells induces progres-
sion into S phase [4]. Since E2F plays central roles in cell proliferation, it has generally been 
thought that defects in the RB pathway upregulate E2F and promote hyperplasia, contributing 
to tumorigenesis. However, it has also been reported that E2F plays a pivotal role in tumor 
suppression. E2F1 knockout mice showed increased incidence of tumor formation [5], sug-
gesting a role of E2F1 in tumor suppression. Overexpression of E2F1 also activates p53, the 
main effector of the p53 pathway, and promotes apoptosis [6], rather than cell proliferation. 
Knocking out p53 attenuates E2F1-induced apoptosis [7], supporting that the induction of 
apoptosis is mediated through activation of p53. Of note, the overexpression of E2F1 activates 
the tumor suppressor gene ARF, an upstream activator of p53 [3]. These observations sug-
gest that E2F plays a pivotal role in tumor suppression by activating ARF, and consequently 
p53. Interestingly, E2F selectively induces the ARF gene upon forced inactivation of pRB, 
which mimics dysfunction of the RB pathway, but not in response to physiological inacti-
vation of pRB by growth stimulation [8, 9]. This observation implies that E2F activates the 
ARF gene specifically in response to oncogenic changes, contributing to tumor suppression. 
Consistent with this notion, the E2F activation of the ARF gene is detected only in cancer 
cells and is not observed in normal growing cells [8, 9]. Thus, E2F stimulation of ARF gene 
expression can serve as a tool to discriminate cancer cells and normal growing cells. In this 
chapter, we describe the roles of E2F in cell proliferation and tumor suppression, focusing on 
the mechanism of E2F dependent, selective regulation of tumor suppressor genes, specifically 
in response to oncogenic changes.
2. E2F plays central roles in cell proliferation
The proliferation of mammalian cells is dependent on growth stimulation, which promotes 
cell cycle progression. Once a cell passes through the restriction (R) point, located in late G1 
phase, it is programmed to automatically proceed to the end of M phase. Thus, the regula-
tion of the R point is a critical determinant of cell cycle progression and cell proliferation. 
Key regulators of the R point are the transcription factor E2F, which activates a repertoire of 
growth-related genes, and the tumor suppressor pRB, which inhibits E2F.
E2F consists of eight family members (E2F1-8), which, based on their function, are divided 
into transcriptional activators (E2F1–E2F3a) and transcriptional repressors (E2F3b–E2F8). E2F 
regulates thousands of genes important for cell cycle progression, DNA replication, DNA 
damage checkpoint, and DNA repair, and plays central roles in cell proliferation [10]. E2F-
modulated cell cycle regulatory genes include Cyclin E [11], Cyclin A [12], and CDC2 [13, 14]. 
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Cyclin E/CDK2 promotes G1 to S phase transition by inactivating pRB through phosphoryla-
tion. Cyclin A/CDK2 promotes progression through S phase. Cyclin A/CDC2 and Cyclin B/
CDC2 promote progression through G2 and progression into and through M phase, respec-
tively. E2F-modulated DNA replication genes include Cdc6 [15], Cdt1 [16], Cyclin E [11], ASK 
[17], and Cdc45 [18]. Origin recognition complex (ORC) binds to replication origins and marks 
where DNA replication takes place. Cdc6 and Cdt1 bind to ORC and promote initiation of 
DNA replication by recruiting the DNA helicase MCM complex to replication origins (Figure 
1). Cyclin E/CDK2 phosphorylates MCM complex and promotes loading of it onto chromatin. 
ASK/Cdc7 activates MCM complex by phosphorylation and Cdc45 recruits DNA polymerase 
α onto chromatin. These E2F targets are essential for DNA replication and G1-S phase tran-
sition [19–23]. Accordingly, knocking out all members of activator-type E2Fs (E2F1~E2F3) 
abolishes cell proliferation [24]. Precise replication of genomic DNA is important to avoid 
mutation. E2F also activates genes involved in DNA damage checkpoint, such as ATM [25] 
and Chk1 [26], and DNA repair, including Claspin [27], BRCA1 [28], and Rad51 [27]. Thus, E2F 
plays a pivotal role in cell proliferation by activating a number of genes critical for cell cycle 
progression and precise DNA replication.
Figure 1. Role of E2F targets in DNA replication. E2F plays central roles in DNA replication by activating genes coding 
for factors involved in initiation of DNA replication, DNA synthesis, DNA damage checkpoint, and DNA repair.
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3. The RB pathway in the control of cell proliferation
pRB is the product of the first identified tumor suppressor gene retinoblastoma (RB1) [29]. pRB 
is the principal regulator of G1 to S phase transition by restraining E2F and plays a crucial role 
in tumor suppression. Based on considerable structural homology, p107 and p130, together 
with pRB, comprise the RB family. During transition from G1 to S phase upon growth stim-
ulation, RB is inactivated through phosphorylation by CDKs, thereby unleashing E2F and 
allowing cell cycle progression.
In quiescence, RB family members (pRB and p130) bind to E2F3b-E2F5 on its target promoters 
and repress their expression (Figure 2). The interaction of RB with the transactivation domain of 
E2F inhibits E2F’s transcriptional activity. Furthermore, RB actively represses the expression of 
E2F target genes by changing chromatin structure through recruitment of histone deacetylase 
(HDAC) [30], histone methyltransferase (Suv39H1) [31], components of the chromatin remod-
eling complex (hBrm and BRG1) [32], and DNA methyltransferase (DNMT1) [33] onto their 
promoters. Upon growth stimulation, D-type cyclin-dependent kinases (CDK4 and 6) are acti-
vated, and inactivate p130 and pRB through phosphorylation inhibit binding of RB to E2F3b-5 
Figure 2. Regulatory mechanism of E2F target genes by E2F and RB. In quiescence, RB family members bind to E2Fs on 
its target promoters and repress their expression. In response to growth stimulation, Cyclin/CDK inactivates RB family 
through phosphorylation, activating E2F and its target gene expression.
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and its target promoters. This leads to the release of E2F from suppression by RB and induces 
its target genes including E2F1-3a and Cyclin E [11, 34]. Cyclin E activates CDK2, which further 
inactivates RB through phosphorylation. This constitutes a positive feedback loop inactivating 
RB and activating E2F, resulting in the further induction of E2F targets and initiation of S phase 
[35]. Thus, regulated functional interactions of E2F and RB play pivotal roles in promoting and 
restraining cell proliferation, respectively. Given its importance in restraining cell proliferation, 
RB is often referred to as a “gatekeeper” in the control of cell proliferation.
Consistent with the critical role of RB in restraining cell proliferation, mutation or deletion of the 
RB1 gene is responsible for retinoblastoma and various types of cancers including breast cancer 
[36], osteosarcoma [37], and small cell lung cancer (SCLC) [38]. Since mutation of p107 and p130 
are uncommon and considering their function and frequency of inactivation, pRB is thought to be 
the pivotal tumor suppressor regulating G1-S phase transition [2, 39]. However, although increased 
tumorigenesis is not detected in p107−/− or p130−/− mice, RB1−/+/p107−/− or RB1−/+/p130−/− compound mice 
are more prone to tumor formation than RB1−/+ mice [40]. This suggests that, upon loss of pRB func-
tion, p107 and p130 can, to some extent, compensate for the tumor suppressor function of pRB [41].
In cancer cells, regulation of G1-S phase transition is lost by the disruption of the RB pathway, 
which is regarded as a hallmark of cancer [2, 42] (Figure 3). Defects in the RB pathway such as 
deletion or mutation of RB1 or silencing of its promoter by hypermethylation have been found in 
breast cancer [36], osteosarcoma [37], and SCLC [38]. Mutation or deletion of the CDK inhibitor 
Figure 3. Defects in the RB pathway. pRB, CDKs, or CDK inhibitors are mutated in cancers, resulting in upregulation of 
E2F activity and its target gene expression.
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p16INK4a or silencing of its promoter by hypermethylation was detected at high frequency in a vari-
ety of cancers including prostate, renal, and colon cancer [43, 44]. Gene amplification and conse-
quent overexpression of cyclin D1 or CDK4 are also detected in various cancers [45, 46]. Upstream 
activators of the Cyclin D1 gene such as c-Myc and Ras are overexpressed or constitutively acti-
vated in cancers [47, 48], suggesting that these mutations also contribute to the overexpression of 
Cyclin D1. Taken together, the RB pathway is, at least at some point, disabled or compromised in 
almost all cancers. Consequently, pRB is functionally inactivated and E2F activity and its target 
gene expression are upregulated, leading to the aberrant cell proliferation. This underscores the 
importance of the RB pathway in tumor suppression.
4. The p53 pathway in the control of cell cycle arrest and apoptosis
p53 plays crucial roles in tumor suppression through the induction of cell cycle arrest or 
apoptosis (programmed cell death). TP53, which codes for p53, is the most frequently 
mutated gene in a variety of cancers including skin cancer [49], nonsmall cell lung cancer 
(NSCLC) [50], and breast cancer [51]. TP53 knockout mice are prone to tumor formation [52, 
53] and enhanced expression of p53 induces cell cycle arrest or apoptosis [54]. The target 
genes involved in cell cycle arrest include CDK inhibitor p21Cip1, 14–3-3σ, and GADD45 [55] 
(Figure 4). CDK inhibitor p21Cip1, which binds to and inhibits Cyclin D/CDK4, 6, Cyclin E/
CDK2, Cyclin A/CDK2, and Cyclin B/CDK1, induces G1 and G2/M arrest [56]. 14–3-3σ binds 
to the phosphatase Cdc25C, which activates Cyclin B/CDK1, and inhibits its activity by the 
translocation of the complex from the nucleus into the cytoplasm [57]. GADD45 binds to and 
inactivates Cdc25C, consequently inhibiting CDK1 to induce G2/M arrest [58]. Activation of 
these genes by p53 is thought to contribute to tumor suppression through the induction of 
cell cycle arrest. The target genes involved in apoptosis include Bax [59], Bak [60], Noxa [61], 
and Puma [62] (Figure 4). Bax and Bak are Bax family members, whose insertion into mito-
chondrial membrane induces release of cytochrome c and apoptosis. Apoptosis induced by 
various stimulations is disabled in Bax/Bak-knocked out cells, indicating that Bax and Bak are 
central players in the induction of programmed cell death [63]. Noxa and Puma directly and 
indirectly activate Bax and Bak [64]. These observations suggest that p53 contributes to tumor 
suppression by the induction of apoptosis through activation of Bax and Bak.
The transcriptional activity of p53 is strictly regulated by its binding factors. The oncogene 
product HDM2, an E3 ubiquitin ligase, induces proteolysis of p53 through ubiquitination and 
inhibits its activity (Figure 5). Under nonstressed conditions, expression of p53 is kept at low 
levels by binding of HDM2. In response to DNA damage, Chk2 and ATM phosphorylate and 
activate p53 by inhibiting binding of HDM2 [65]. The tumor suppressor ARF stabilizes p53 
by inhibiting HDM2 activity though its sequestration into the nucleolus [66]. Importantly, the 
expression of ARF is induced by oncogenic changes such as defects in the RB pathway including 
overexpression of c-myc and Ras [67], and expression of ARF is upregulated in various cancer 
cells [68]. Based on these observations, ARF is described as a “sensor of oncogenic stresses” and 
is thought to play crucial roles in tumor suppression, through up-regulation of p53, in response 
to oncogenic changes. Supporting the importance of its function, mutation, and deletion of 
ARF is detected in various cancers [69] and ARF−/− mice are prone to tumor formation [70]. The 
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signal transduction network, from ARF to p53, is referred to as the p53 pathway. Studies using 
animal models revealed that forced inactivation of the RB and p53 pathways efficiently induce 
tumorigenesis, suggesting that both play pivotal roles in tumor suppression [71, 72].
5. Pivotal roles of E2F in tumor suppression
E2F plays crucial roles not only in cell proliferation but also in tumor suppression. E2F1−/− 
mice are prone to tumor formation [5] and overexpression of E2F1 induces apoptosis, sug-
gesting that E2F contributes to tumor suppression through the induction of apoptosis. 
Figure 4. Induction of cell cycle arrest or apoptosis by p53. p53 contributes to cell cycle arrest through the induction of 
p21Cip1, 14–3-3σ, and GADD45, and apoptosis through Bax, Bak, Noxa, and Puma.
Figure 5. The mechanism of ARF activation of p53. In response to oncogenic changes, ARF stabilizes p53 by inhibiting 
HDM2 activity.
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The target genes involved in apoptosis include ARF and TAp73 [7, 67] (Figure 6). ARF is 
an upstream activator of p53 and plays an important role in transmitting oncogenic signals 
to p53. The transcription factor TAp73 is a homolog of p53 and induces apoptosis through 
upregulation of p53 target genes in a p53-independent manner [73]. Apoptosis induced by 
the overexpression of E2F1 is attenuated in TP53−/− cells and TAp73−/− cells, and is disabled in 
TP53−/−/TAp73−/− cells [7]. Moreover, PPP1R13B and JMY, whose products function as coactiva-
tors of p53 and TAp73, are also E2F targets (Figure 6) [74], indicating that E2F1 induces apop-
tosis primarily via p53 and TAp73. Other tumor suppressor genes that are E2F targets include 
MOAP1, RASSF1, and BIM (Figure 6). MOAP1 forms a complex with RASSF1 and activates 
the proapoptotic protein Bax. BIM is a member of the BH3-only family, which induces apop-
tosis through direct or indirect activation of Bax [75]. In addition, Bax is also a target of p53 
and TAp73 [60]. These observations indicate that E2F suppresses tumor formation by the 
induction of apoptosis through upregulation of p53, TAp73, and their downstream effectors. 
Importantly, we demonstrated that E2F activates ARF and TAp73 genes upon forced inactiva-
tion of pRB, which mimics dysfunction of the RB pathway, but not in response to the physi-
ological inactivation of pRB through growth stimulation [8, 9]. Moreover, a search for genes 
regulated by E2F in a similar manner to ARF and TAp73 identified PPP1R13B, JMY, MOAP1, 
RASSF1, and BIM [76]. These results suggest that E2F contributes to tumor suppression by 
inducing these genes specifically upon dysfunction of the RB pathway. Consistent with this 
Figure 6. The pathway of E2F-induced apoptosis. In response to oncogenic changes, E2F induces apoptosis through 
upregulation of p53, TAp73, and their downstream effectors.
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notion, E2F activity that activates the ARF and TAp73 genes is detected only in cancer cells and 
is not present in normal cells [8, 9], underscoring the importance of E2F in tumor suppression. 
Since E2F selectively activates these tumor suppressor genes in the context of dysfunctional 
pRB, such E2F activity is referred to as “deregulated E2F activity.” This E2F-dependent tumor 
suppression mechanism implies that disruption of both the p53 and RB pathways is necessary 
for tumor formation.
6. Regulation of E2F activity to induce apoptosis
Among E2F family members, activator-type E2Fs (E2F1-3) induce tumor suppressor genes 
such as ARF and TAp73, with E2F1 exhibiting the highest such activity [9, 76]. Therefore, to 
understand the regulation of tumor suppression by E2F, elucidation of the mechanism, by 
which E2F1 activates tumor suppressor genes, is important. Several factors that bind E2F1 
and affect its activity are summarized in Table 1. TopBP1 is phosphorylated by Akt/PKB upon 
growth stimulation. The phosphorylated TopBP1 associates with E2F1 [77] and recruits Brg1, 
a component of chromatin remodeling complex, to E2F1, resulting in the inhibition of E2F1 
induction of the ARF gene [78]. Jab1, a coactivator of c-Jun [79], binds to E2F1 through the 
marked box domain and promotes the induction of apoptosis by E2F1 [80, 81]. RIP140 and 
VHL repress the activation of the ARF promoter by E2F1 [82, 83]. ARF also functions as a 
transcription cofactor that binds to the transactivation domain of E2F1 to repress E2F1 activa-
tion of the ARF promoter [84]. PRMT5 methylates E2F1 on arginine residues 111 and 113, and 
destabilizes E2F1 [85]. SENP8 deNEDDylates (removes NEDD8) and stabilizes E2F1, result-
ing in enhancing activation of TAp73 promoter [86]. Sirt1, a histone deacetylase, represses E2F 
stimulation of the TAp73 promoter [87]. These studies revealed that E2F’s ability to activate 
tumor suppressor genes is regulated by various factors such as transcription cofactors, post-
translational modifiers, and histone modifiers. The mechanism of the regulation of E2F activ-
ity by these factors is not known in detail and its elucidation is imperative.
Gene name Function Monitoring promoter Effect on E2F activity
Jab1 Transcription cofactor of c-jun ARF Upregulation
SENP8 Sentrin-specific protease TAp73 Upregulation
ARF Inhibitor of HDM2, transcription cofactor of c-myc ARF Repression
PRMT5 Methylase TAp73 Repression
RIP140 Transcription cofactor of estrogen receptor ARF Repression
Sirt1 Histone deacetylase TAp73 Repression
TopBP1 Transcription cofactor of Miz ARF Repression
VHL E3 ubiquitin ligase, transcription cofactor of p53 ARF Repression
Table 1. E2F-binding factors and their effects on its activity to activate tumor suppressor genes.
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7. Utility of deregulated E2F activity in cancer cell-specific gene 
expression
In cancer treatment, specifically targeting cancer cells is important for optimal therapeutic effi-
cacy. One strategy is to utilize a cancer-specific promoter to express a cytotoxic gene or a viral 
gene required for the replication. By regulating a suicide gene such as HSV-TK or a proapoptotic 
gene under the control of cancer-specific promoters, the gene is expressed specifically in cancer 
cells and causes cell death [88–90]. Alternatively, by regulating a viral gene required for viral 
replication under the control of these promoters, the gene is expressed specifically in cancer cells, 
allowing viral replication and cell lysis in a cancer cell-specific manner [91–93]. In this approach, 
therapeutic effects and side effects are dependent on the promoter activity in cancer cells and nor-
mal cells, respectively. Therefore, a promoter with optimal cancer cell-specificity should be used.
For a promoter to be cancer specific, it should have two important characteristics. First, the pro-
moter should have low activity in normal cells to avoid side effects. Second, it should exhibit 
high activity in a wide variety of cancer cells for maximum therapeutic effects. As promoters 
thought to exemplify these parameters, hTERT and E2F1 promoters have been utilized. hTERT 
is a catalytic component of telomerase, which is not expressed in most somatic cells but is 
present in many types of cancers [94]. Thus, the hTERT promoter exhibits strong promoter 
activity in many types of cancer cells. However, given that normal stem cells also express 
hTERT, the hTERT promoter may exhibit strong promoter activity in these cells [95]. The E2F1 
promoter is activated by E2F, whose activity is upregulated in cancer cells due to defects in the 
RB pathway. Thus, E2F1 promoter also exhibits strong promoter activity in many types of can-
cer cells. However, the E2F1 promoter is also stimulated by physiological E2F activity induced 
by growth stimulation and thus has a strong promoter activity in normal growing cells [34].
In contrast to the hTERT and E2F1 promoters, which may exhibit strong promoter activity in 
normal cells, the tumor suppressor ARF promoter, which specifically responds to deregulated 
E2F activity, is thought to be a better candidate. E2F activity stimulating the ARF promoter, is 
detected only in cancer cells and not in normal cells [8]. ARF is expressed at high levels in vari-
ous cancer cells, but not in normally growing cells [68]. Furthermore, the activity of the ARF 
promoter is detected specifically in tumor tissues and not in normal tissues in vivo as revealed 
using ARFGFP/GFP mice [96]. These observations indicate that the ARF promoter shows optimal 
cancer cell specificity in a wide variety of cell types and has excellent therapeutic potential.
We showed that the ARF promoter exhibited greater cancer cell specificity than the E2F1 pro-
moter [97]. Adenovirus expressing HSV-TK, a suicide gene, under the control of the ARF pro-
moter (Ad-ARF-TK) had more selective cytotoxicity in cancer cells than the analogous E2F1 
promoter construct [97]. Moreover, overexpression of the CDK inhibitor p21Cip upregulated 
deregulated E2F activity specifically in cancer cells and augmented cancer cell-specific cyto-
toxicity of Ad-ARF-TK [98]. These observations underscore the utility of the ARF promoter 
and deregulated E2F activity in mediating cancer-specific gene expression (Figure 7, upper 
panel). Furthermore, overexpression p21Cip alone could induce E2F dependent apoptosis spe-
cifically in cancer cells [98], suggesting that induction or enhancement of deregulated E2F 
activity could be a drug target to induce cancer cell-specific apoptosis (Figure 7, lower panel). 
It must be worth testing whether drug-based CDK inhibitors also exhibit similar effects to 
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p21Cip. Since p21Cip inhibits most of CDKs, identification of responsible CDK, which inhibits 
deregulated E2F activity, is also important. By using specific inhibitor to the responsible CDK, 
deregulated E2F activity could be more efficiently enhanced. The combination of deregu-
lated E2F-mediated suicide gene therapy and enhancement of deregulated E2F activity using 
appropriate CDK inhibitor should also improve deregulated E2F-mediated cancer therapy.
8. Conclusion
E2F is the principal target of the tumor suppressor pRB and defects in the RB pathway are 
observed in almost all cancers. Upon oncogenic changes, E2F activates ARF, an upstream acti-
vator of p53 and TAp73, resulting in the induction of apoptosis. Importantly, the E2F activity 
to stimulate ARF and TAp73 expression is not induced by the physiological activation of E2F, 
such as growth stimulation. Therefore, E2F suppresses tumor formation by inducing apop-
tosis specifically in response to oncogenic changes through the activation of ARF and TAp73. 
Moreover, deregulated E2F-dependent activation of the ARF gene is observed only in cancer 
cells, and not in normal cells, suggesting that deregulated E2F activity represents a beneficial 
tool to specifically target cancer cells in cancer treatment.
Figure 7. Application of deregulated E2F activity for cancer-specific treatment. Application 1: ARF promoter, which 
responds to deregulated E2F activity in cancer cells but not to physiological E2F activity in normal cells, drives suicide 
gene expression, and induces apoptosis specifically in cancer cells. Application 2: Upregulation of deregulated E2F 
activity by CDK inhibitors activates endogenous tumor suppressor genes and induces apoptosis specifically in cancer 
cells.
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Evidence supporting the potential availability of deregulated E2F activity in cancer therapy is 
accumulating. The regulation of suicide genes by the ARF promoter has more selective cyto-
toxicity in cancer cells than the analogous E2F1 promoter construct. Moreover, overexpression 
of p21Cip upregulates deregulated E2F activity and augments cancer-specific cytotoxicity of the 
ARF promoter construct. Furthermore, overexpression p21Cip alone can induce E2F-dependent 
apoptosis specifically in cancer cells. Therefore, deregulated E2F activity can drive selective gene 
expression and induce apoptosis specifically in cancer cells, supporting its therapeutic potential 
in a variety of cancers. The development of cancer therapies based upon deregulated E2F activ-
ity will require detailed characterization of the components and molecular mechanisms under-
lying its functional role in oncogenesis and tumor suppression and merits further investigation.
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Abbreviations
ARF Alternative reading frame
ASK Activator of S-phase kinase
ATM Ataxia telangiectasia mutated
Bax Bcl-2-associated X protein
Bak Bcl-2 homologs antagonist/killer
BIM BCL-2 interacting mediator of cell death
BRCA1 Breast cancer susceptibility genes 1
BRG1 Brahma-related gene-1
Cdc Cell division cycle
CDK Cyclin-dependent kinase
Cdt1 Chromatin licensing and DNA replication factor 1
Chk1 Checkpoint kinase 1
Chk2 Checkpoint kinase 2
DNMT1 DNA methyltransferase 1
E2F E2 transcription factor
GADD45 Growth arrest and DNA-damage-inducible gene 45
GFP Green fluorescent protein
hBrm human Brahma
HDAC histone deacetylase
HDM2 Human double minute 2
Gene Expression and Regulation in Mammalian Cells - Transcription Toward the Establishment of Novel Therapeutics154
HSV-TK Herpes simplex virus-1 thymidine kinase
hTERT Human telomerase reverse transcriptase
Jab1 Jun activation domain-binding protein 1
JMY Junction-mediating and regulatory protein
MCM Minichromosome maintenance
MOAP1 Modulator of apoptosis 1
NSCLC nonsmall cell lung cancer
ORC Origin recognition complex
PKB protein kinase B
PPP1R13B Protein phosphatase 1 regulatory subunit 13B
PRMT5 Protein arginine methyltransferase 5
Puma p53 upregulated modulator of apoptosis
RASSF1 Ras association domain family member 1
RB Retinoblastoma
RIP140 Receptor-interacting protein 140
SCLC Small cell lung cancer
SENP8 Sentrin specific protease family member
Suv39H1 suppressor of variegation 3–9 homolog 1
TopBP1 DNA topoisomerase II-binding protein 1
VHL Von Hippel–Lindau
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